The study is being conducted to evaluate the efficacy, safety and the population pharmacokinetic characteristics of Dexmedetomidine Hydrochloride Microneedles for preoperative sedation in children
Aged 2 years to 6 years (inclusive ), any genders;
Scheduled to undergo general anesthesia for surgery/procedure
American Society of Anesthesiologists（ASA） I~II
Provide written informed consent from the legal guardian
Allergy to any component of the Dexmedetomidine Hydrochloride Microneedle Patch, history of allergy to other sedative drugs, or known allergy to α2-adrenergic receptor-related products or excipients;
Having received other sedative-hypnotic or analgesic drugs prior to randomization, where the time since last dose is less than 7 half-lives;
History of bronchial asthma, chronic respiratory diseases, or other severe respiratory system diseases;
History of neurological diseases such as ischemic encephalopathy encephalopathy, craniocerebral injury, etc., which in the investigator's judgment may affect the evaluation of the investigational product;